A PYMNTS Company

Sanofi Eyes Insmed Acquisition

 |  November 20, 2026
Sanofi

French pharmaceutical company Sanofi is considering a takeover of US biotechnology firm Insmed as it looks to expand its drug portfolio and strengthen future revenue growth, Bloomberg News reported Thursday, citing people familiar with the matter.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Sanofi has been working with advisers to evaluate a potential acquisition of the New Jersey-based company, according to Bloomberg. Discussions remain preliminary, and there is no guarantee that a transaction will proceed. Other potential buyers could also emerge.

    Insmed specializes in treatments for serious respiratory diseases, including Brinsupri, a medicine for non-cystic fibrosis bronchiectasis, and Arikayce, which treats certain bacterial lung infections.

    The company reported third-quarter revenue of $524.4 million, up 268% from a year earlier, according to financial figures cited by Bloomberg. Its market capitalization stood at approximately $26.6 billion before the takeover report.

    The potential deal comes as Sanofi seeks new growth opportunities amid concerns about its reliance on Dupixent, a leading treatment for inflammatory conditions that faces eventual patent expirations.

    Related: Sanofi Reaches Settlement in US Antitrust Dispute Over Lantus Insulin

    Sanofi Chief Executive Officer Belén Garijo has identified acquisitions as an important part of the company’s strategy, Bloomberg reported. The drugmaker has also been working to improve research productivity following setbacks involving experimental medicines.

    A purchase of Insmed would strengthen Sanofi’s respiratory medicine business and provide additional commercial products as it works to expand its development pipeline.

    The potential transaction would also follow Sanofi’s sale of a controlling stake in consumer healthcare business Opella, which generated approximately €10 billion in net cash proceeds and increased its financial flexibility.

    Bloomberg reported that both companies declined to comment on the discussions.

    Source: Bloomberg